Cognitive impairment in older patients with breast cancer before systemic therapy: Is there an interaction between cancer and comorbidity?

Journal of Clinical Oncology

Volumn 32, Issue 18, 2014, Pages 1909-1918

  Mandelblatt, Jeanne S ^a   Stern, Robert A ^b   Luta, Gheorghe ^a   McGuckin, Meghan ^a   Clapp, Jonathan D ^a   Hurria, Arti ^c   Jacobsen, Paul B ^d   Faul, Leigh Anne ^a   Isaacs, Claudine ^a   Denduluri, Neelima ^a,f   Gavett, Brandon ^b   Traina, Tiffany A ^g,h   Johnson, Patricia ^b,e   Silliman, Rebecca A ^b   Turner, R Scott ^a   Howard, Darlene ^a   Van Meter, John W ^a   Saykin, Andrew ⁱ   Ahles, Tim ^g  

^a GEORGETOWN UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Virginia Cancer Specialists PC   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DEPRESSION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FATIGUE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SYSTEMIC THERAPY; BREAST TUMOR; COGNITION; COMORBIDITY; ETHNOLOGY; MILD COGNITIVE IMPAIRMENT; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COGNITION; COMORBIDITY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MILD COGNITIVE IMPAIRMENT; NEOPLASM STAGING; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; QUESTIONNAIRES; UNITED STATES;

EID: 84905455466     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.2050     Document Type: Article

References (96)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. National Comprehensive Cancer Network: Breast cancer treatment guidelines. http://www.nccn.org/professionals/physician-gls/f-guidelines. asp#breast
3. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010.4
4. Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
5. Bender CM: Chemotherapy may have small to moderate negative effects on cognitive functioning. Cancer Treat Rev 32:316-319, 2006
6. Ganz PA, Bower JE, Kwan L, et al: Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30:S99-S108, 2013 (suppl)
7. Collins B, MacKenzie J, Tasca GA, et al: Cognitive effects of chemotherapy in breast cancer patients: A dose-response study. Psychooncology 227:1517-1527, 2013
8. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002 (Pubitemid 34072533)
9. Ahles TA, Saykin AJ, Noll WW, et al: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12:612-619, 2003 (Pubitemid 37086736)
10. Koppelmans V, Breteler MM, Boogerd W, et al: Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30:1080-1086, 2012
11. Eberhardt B, Dilger S, Musial F, et al: Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol 132:234-240, 2006 (Pubitemid 43144259)
12. Ahles TA, Root JC, Ryan EL: Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. J Clin Oncol 30:3675-3686, 2012
13. Jim HS, Phillips KM, Chait S, et al: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587, 2012
14. Jansen SJ, Otten W, Baas-Thijssen MC, et al: Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients. J Clin Oncol 23:6623-6630, 2005 (Pubitemid 46190256)
15. Anderson-Hanley C, Sherman ML, Riggs R, et al: Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967-982, 2003 (Pubitemid 37428441)
16. Correa DD, Ahles TA: Neurocognitive changes in cancer survivors. Cancer J 14:396-400, 2008
17. Stewart A, Bielajew C, Collins B, et al: A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20:76-89, 2006
18. Small BJ, Rawson KS, Walsh E, et al: Catechol-O-methyltransferase genotype modulates cancer treatment-related cognititve deficits in breast cancer survivors. Cancer 117:1369-1376, 2011
19. Phillips KA, Aldridge J, Ribi K, et al: Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 126:221-226, 2011
20. Hermelink K, Henschel V, Untch M, et al: Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: Results of a multicenter, prospective, longitudinal study. Cancer 113:2431-2439, 2008
21. Shaffer VA, Merkle EC, Fagerlin A, et al: Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: Findings from a prospective cohort study. Med Care 50:849-855, 2012
22. Ording AG, Jensen AB, Cronin-Fenton D, et al: Null association between tamoxifen use and dementia in Danish breast cancer patients. Cancer Epidemiol Biomarkers Prev 22:993-996, 2013
23. Ahles TA, Saykin AJ, McDonald BC, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010
24. Wefel JS, Lenzi R, Theriault R, et al: "Chemobrain" in breast carcinoma? A prologue. Cancer 101:466-475, 2004
25. Scherling C, Collins B, Mackenzie J, et al: Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: A functional magnetic resonance imaging study. J Clin Exp Neuropsychol 34:543-560, 2012
26. Cimprich B, Reuter-Lorenz P, Nelson J, et al: Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32:324-331, 2010
27. Reuter-Lorenz PA, Cimprich B: Cognitive function and breast cancer: Promise and potential insights from functional brain imaging. Breast Cancer Res Treat 137:33-43, 2013
28. Cimprich B, So H, Ronis DL, et al: Pretreatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology 14:70-78, 2005 (Pubitemid 40124675)
29. Rasmussen LS, Johnson T, Kuipers HM, et al: Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand 47:260-266, 2003 (Pubitemid 36384662)
30. Johnson T, Monk T, Rasmussen LS, et al: Posteroperative cognitive dysfunction in middle aged patients. Anesthesiology 96:1351-1357, 2002 (Pubitemid 34587203)
31. Moretti R, Torre P, Antonello RM, et al: Vitamin B12 and folate depletion: Clinical evidence in a neurological population. Neurologist 10:338-343, 2004 (Pubitemid 39492079)
32. Wefel JS, Meyers CA: Cancer as a risk factor for dementia: A house built on shifting sand. J Natl Cancer Inst 97:788-789, 2005 (Pubitemid 40909116)
33. Wilson CJ, Finch CE, Cohen HJ: Cytokines and cognition: The case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50:2041-2056, 2002 (Pubitemid 35462453)
34. Joshi G, Aluise CD, Cole MP, et al: Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: Implications for oxidative stress-mediated chemobrain. Neuroscience 166:796-807, 2010
35. Blasiak J, Arabski M, Krupa R, et al: Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res 554:139-148, 2004 (Pubitemid 39140822)
36. Laws SM, Clarnette RM, Taddei K, et al: APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 7:768-775, 2002 (Pubitemid 34984954)
37. Farrer LA, Cupples LA, Haines JL, et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis - APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349-1356, 1997 (Pubitemid 27449696)
38. von Zglinicki T, Martin-Ruiz CM: Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 5:197-203, 2005 (Pubitemid 40601647)
39. Schröder CP, Wisman GB, de Jong S, et al: Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 84:1348-1353, 2001 (Pubitemid 32522103)
40. Campisi J: Aging, cellular senescence, and cancer. Annu Rev Physiol 75:685-705, 2013
41. Velarde MC, Demaria M, Campisi J: Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 38:17-27, 2013
42. Ahles TA, Saykin AJ, McDonald BC, et al: Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110:143-152, 2008 (Pubitemid 351793851)
43. Hurria A, Rosen C, Hudis C, et al: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 54:925-931, 2006 (Pubitemid 43847029)
44. Hurria A, Goldfarb S, Rosen C, et al: Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 98:343-348, 2006 (Pubitemid 44195605)
45. Freilich RJ, Delattre JY, Monjour A, et al: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435-439, 1996 (Pubitemid 26081327)
46. Yamada TH, Denburg NL, Beglinger LJ, et al: Neuropsychological outcomes of older breast cancer survivors: Cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 22:48-54, 2010
47. Boston University School of Medicine: TLC study. http://www.bumc.bu.edu/ tlcstudy/
48. Saykin AJ, Ahles TA, McDonald BC: Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8:201-216, 2003 (Pubitemid 37474731)
49. Head D, Snyder AZ, Girton LE, et al: Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex 15:732-739, 2005 (Pubitemid 40696113)
50. Hedden T, Gabrieli JD: Healthy and pathological processes in adult development: New evidence from neuroimaging of the aging brain. Curr Opin Neurol 18:740-747, 2005 (Pubitemid 41669150)
51. McDonald BC, Conroy SK, Ahles TA, et al: Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Res Treat 123:819-828, 2010
52. McDonald BC, Conroy SK, Smith DJ, et al: Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study. Brain Behav Immun 30:S117-S125, 2013 (suppl)
53. Wefel JS, Vardy J, Ahles T, et al: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708, 2011
54. Weintraub S, Salmon D, Mercaldo N, et al: The Alzheimer's Disease Centers' Uniform Data Set (UDS): The neuropsychologic test battery. Alzheimer Dis Assoc Disord 23:91-101, 2009
55. Stern RA, White T: Neuropsychological Assessment Battery (NAB). Lutz, FL, Psychological Assessment Resources, 2003
56. Hurria A, Lachs M: Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer? Breast Cancer Res Treat 103:259-268, 2007 (Pubitemid 46944514)
57. Reitan R, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ, Neuropsychology Press, 1985
58. Wechsler D: Wechsler Adult Intelligence Scale (ed 3). San Antonio, TX, Harcourt Assessment, 1997
59. Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test: Experimental Edition (ed 2). Boston, MA, Kaplan and Goodglass, 1983
60. Morris JC, Heyman A, Mohs RC, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part I - Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39:1159-1165, 1989 (Pubitemid 19239715)
61. Benton AL: Neuropsychological assessment. Annu Rev Psychol 45:1-23, 1994
62. Jacobs SR, Jacobsen PB, Booth-Jones M, et al: Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage 33:13-23, 2007 (Pubitemid 46017075)
63. Mandelblatt JS, Hurria A, McDonald BC, et al: Cognitive effects of cancer and its treatments at the intersection of aging: What do we know; what do we need to know? Semin Oncol 40:709-725, 2013
64. Stern RA, Silva SG, Chaisson N, et al: Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol 53:148-153, 1996 (Pubitemid 26055261)
65. Craig CL, Marshall AL, Sjöström M, et al: International physical activity questionnaire: 12- country reliability and validity. Med Sci Sports Exerc 35:1381-1395, 2003 (Pubitemid 36936159)
66. Radloff LS: The CES-D scale: A self-report depression scale for research in the general population. Appl Pscyhol Meas 1:385-401, 1977
67. Dozeman E, van Schaik DJF, van Marwijk HWJ, et al: The Center for Epidemiological Studies Depression Scale (CES-D) is an adequate screening instrument for depressive and anxiety disorders in a very old population living in residential homes. Int J Geriatr Psychiatry 26:239-246, 2011
68. Spielberger CD: Manual for the State-Trait Anxiety Inventory (STAI: Form Y). Palo Alto, CA, Consulting Psychologists Press, 1983
69. Cella D: Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 25:43-46, 1998 (suppl 7)
70. Ware J, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233, 1996 (Pubitemid 126433231)
71. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986, 1997 (Pubitemid 27106280)
72. Schilling V, Jenkins V, Morris R: The effects of adjuvant chemotherapy on cognition in women with breast cancer: Preliminary results of an observational study. Breast 14:142-150, 2005 (Pubitemid 40353042)
73. Schilder CM, Seynaeve C, Linn SC, et al: The impact of different definitions and reference groups on the prevalence of cognitive impairment: A study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psychooncology 19:415-422, 2010
74. Shilling V, Jenkins V, Trapala IS: The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 95:125-129, 2006
75. Wefel JS, Saleeba AK, Buzdar AU, et al: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348-3356, 2010
76. Jansen CE, Cooper BA, Dodd MJ, et al: A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647-1656, 2011
77. Ottati A, Feuerstein M: Brief self-report measure of work-related cognitive limitations in breast cancer survivors. J Cancer Surviv 7:262-273, 2013
78. Cimprich B, Visovatti M, Ronis DL: The Attentional Function Index: A self-report cognitive measure. Psychooncology 20:194-202, 2011
79. Mehlsen M, Pedersen AD, Jensen AB, et al: No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 18:248-257, 2009
80. Schilder CM, Seynaeve C, Linn SC, et al: Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: Findings from the neuropsychological TEAM side-study. Psychooncology 21:479-487, 2012
81. Schilder CM, Seynaeve C, Linn SC, et al: Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol 76:133-141, 2010
82. Kesler S, Janelsins M, Koovakkattu D, et al: Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapytreated breast cancer survivors. Brain Behav Immun 30:S109-S116, 2013 (suppl)
83. Pomykala KL, Ganz PA, Bower JE, et al: The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 7:511-523, 2013
84. Pal SK, Hurria A: Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 28:4086-4093, 2010
85. van Himbergen TM, Beiser AS, Ai M, et al: Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer's disease: Results from the Framingham Heart Study. Arch Neurol 69:594-600, 2012
86. Arcidiacono B, Iiritano S, Nocera A, et al: Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res [epub ahead of print on June 4, 2012]
87. Donohoe CL, Doyle SL, Reynolds JV: Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 3:12, 2011
88. Parekh AK, Barton MB: The challenge of multiple comorbidity for the US health care system. JAMA 303:1303-1304, 2010
89. Chang SS, Weiss CO, Xue QL, et al: Patterns of comorbid inflammatory diseases in frail older women: The Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 65:407-413, 2010
90. Salive ME: Multimorbidity in older adults. Epidemiol Rev [epub ahead of print on January 31, 2013]
91. Yancik R, Ries LA: Cancer in older persons: An international issue in an aging world. Semin Oncol 31:128-136, 2004 (Pubitemid 38481234)
92. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007 (Pubitemid 46860271)
93. Driver JA, Beiser A, Au R, et al: Inverse association between cancer and Alzheimer's disease: Results from the Framingham Heart Study. BMJ 344:e1442, 2012
94. Saadat M: Apolipoprotein E (APOE) polymorphisms and susceptibility to breast cancer: A meta-analysis. Cancer Res Treat 44:121-126, 2012
95. Bishop NA, Lu T, Yankner BA: Neural mechanisms of aging and cognitive decline. Nature 464:529-535, 2010
96. Brainerd CJ, Reyna VF, Petersen RC, et al: Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study. Neuropsychology 25:679-689, 2011